GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » Price-to-Free-Cash-Flow

Nascent Biotech (Nascent Biotech) Price-to-Free-Cash-Flow : N/A (As of May. 28, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech Price-to-Free-Cash-Flow?

As of today (2024-05-28), Nascent Biotech's share price is $0.099. Nascent Biotech's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01. Hence, Nascent Biotech's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Nascent Biotech's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 7 years, Nascent Biotech's highest Price-to-Free-Cash-Flow Ratio was 57.00. The lowest was 10.54. And the median was 24.70.

NBIO's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.14
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Nascent Biotech's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.01.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 2.10% per year.

During the past 7 years, Nascent Biotech's highest 3-Year average Free Cash Flow per Share Growth Rate was 33.20% per year. The lowest was 2.10% per year. And the median was 23.00% per year.


Nascent Biotech Price-to-Free-Cash-Flow Historical Data

The historical data trend for Nascent Biotech's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech Price-to-Free-Cash-Flow Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - 14.25 -

Nascent Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nascent Biotech's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Nascent Biotech's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Biotech's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's Price-to-Free-Cash-Flow falls into.



Nascent Biotech Price-to-Free-Cash-Flow Calculation

Nascent Biotech's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.099/-0.008
=N/A

Nascent Biotech's Share Price of today is $0.099.
Nascent Biotech's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Nascent Biotech  (OTCPK:NBIO) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Nascent Biotech Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Nascent Biotech (Nascent Biotech) Business Description

Traded in Other Exchanges
N/A
Address
631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Executives
Lowell Thomas Holden director, officer: CFO 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick director, officer: President 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price director, officer: Senior VP Business Development 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas director 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy director, officer: CEO 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121